This review looked at the effectiveness of statins in the elderly and concluded that statins reduce mortality by more than was thought previously. The authors' conclusions are likely to be reliable.
Study selection
Placebo-controlled randomised controlled trials (RCTs) of statin treatment recruiting at least 50 elderly CHD participants (aged 65 years or older) who were followed up for at least six months were eligible for inclusion. Eligible trials also had to report all-cause mortality, CHD mortality, nonfatal myocardial infarction (MI), need for revascularisation or stroke as an outcome measure.
The statin used in included studies was either simvastatin (20-40mg), pravastatin (40mg) or fluvastatin (80mg). The use of lipid-lowering drugs in the control groups varied between 2 per cent and 24 per cent. The mean (weighted) follow up period was 4.9 years. Most studies recruited participants who had an MI or coronary artery disease. The mean age range was 66.8 to 75.6 years. The primary outcomes were either major adverse cardiac events or angiographic progression of coronary artery disease.
Three reviewers selected studies for inclusion.
Assessment of study quality
Studies were assessed for concealment of randomised assignment, completeness of follow up, use of intention-to-treat analysis, similarity at baseline, and equality of (non-study) treatment. The authors did not state how the validity assessment was performed.
Data extraction
Data on the number of outcomes in the intervention and comparator groups were extracted and relative risks (RR) and 95% credible intervals (CrI) were calculated. Investigators were contacted to obtained unpublished data for studies with elderly subgroups. Two reviewers extracted data, which were independently verified by a third reviewer. Disagreements were resolved by consensus.
Methods of synthesis
A Bayesian hierarchical model was used to pool the main outcome data. Detailed methods for the Bayesian analysis were reported, although the authors did not report details about weighting of studies. Sensitivity analyses were conducted, including one for adjusting for the proportion of patients with prior MI. Numbers needed to treat were calculated. Non-Bayesian (Frequentist) analyses were also conducted.
